Associations - NK cell stimulant

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval pomalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	pomalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval pomalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + pomalidomide Sensitive: A2 - Guideline selinexor + pomalidomide Sensitive : A2	selinexor + pomalidomide Sensitive: A2 - Guideline selinexor + pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2
No biomarker	Glioblastoma	No biomarker	Glioblastoma	CYNK-001 Sensitive: B - Late Trials CYNK-001 Sensitive : B	CYNK-001 Sensitive: B - Late Trials CYNK-001 Sensitive : B
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	FT516 Sensitive: B - Late Trials FT516 Sensitive : B	FT516 Sensitive: B - Late Trials FT516 Sensitive : B
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	CYNK-001 Sensitive: B - Late Trials CYNK-001 Sensitive : B	CYNK-001 Sensitive: B - Late Trials CYNK-001 Sensitive : B
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	CYNK-101 Sensitive: B - Late Trials CYNK-101 Sensitive : B	CYNK-101 Sensitive: B - Late Trials CYNK-101 Sensitive : B
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	CYNK-101 Sensitive: B - Late Trials CYNK-101 Sensitive : B	CYNK-101 Sensitive: B - Late Trials CYNK-101 Sensitive : B
No biomarker	Hematological Malignancies	No biomarker	Hematological Malignancies	SAR443579 Sensitive: B - Late Trials SAR443579 Sensitive : B	SAR443579 Sensitive: B - Late Trials SAR443579 Sensitive : B
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AFM13/AB-101 Sensitive: B - Late Trials AFM13 / AB-101 Sensitive : B	AFM13/AB-101 Sensitive: B - Late Trials AFM13 / AB-101 Sensitive : B
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	IDP-023 Sensitive: B - Late Trials IDP-023 Sensitive : B	IDP-023 Sensitive: B - Late Trials IDP-023 Sensitive : B
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	IDP-023 Sensitive: B - Late Trials IDP-023 Sensitive : B	IDP-023 Sensitive: B - Late Trials IDP-023 Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	SNK01 Sensitive: C2 – Inclusion Criteria SNK01 Sensitive : C2	SNK01 Sensitive: C2 – Inclusion Criteria SNK01 Sensitive : C2
CRBN underexpression	Multiple Myeloma	CRBN underexpression	Multiple Myeloma	pomalidomide Resistant: C3 – Early Trials pomalidomide Resistant : C3	pomalidomide Resistant: C3 – Early Trials pomalidomide Resistant : C3
SPARC-L + IKZF3 elevation	Multiple Myeloma	SPARC-L + IKZF3 elevation	Multiple Myeloma	KappaMab Resistant: C3 – Early Trials KappaMab Resistant : C3	KappaMab Resistant: C3 – Early Trials KappaMab Resistant : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab + SNK01 Sensitive: C3 – Early Trials pembrolizumab + SNK01 Sensitive : C3	pembrolizumab + SNK01 Sensitive: C3 – Early Trials pembrolizumab + SNK01 Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + SNK01 Sensitive: C3 – Early Trials pembrolizumab + SNK01 Sensitive : C3	pembrolizumab + SNK01 Sensitive: C3 – Early Trials pembrolizumab + SNK01 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	cetuximab + SNK01 Sensitive: C3 – Early Trials cetuximab + SNK01 Sensitive : C3	cetuximab + SNK01 Sensitive: C3 – Early Trials cetuximab + SNK01 Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3
KRAS mutation	Multiple Myeloma	KRAS mutation	Multiple Myeloma	trametinib + daratumumab + pomalidomide Sensitive: C4 – Case Studies trametinib + daratumumab + pomalidomide Sensitive : C4	trametinib + daratumumab + pomalidomide Sensitive: C4 – Case Studies trametinib + daratumumab + pomalidomide Sensitive : C4
TNFRSF17 underexpression	Multiple Myeloma	TNFRSF17 underexpression	Multiple Myeloma	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + CYNK-101 Sensitive: D – Preclinical trastuzumab + CYNK-101 Sensitive : D	trastuzumab + CYNK-101 Sensitive: D – Preclinical trastuzumab + CYNK-101 Sensitive : D

NK cell stimulant

NK cell stimulant

Associations(41)

Associations
(41)